

Japan approves world's first transdermal β 1-blocker patch

05 July 2013 | Regulatory | By BioSpectrum Bureau



Singapore: Japan-based Nitto Denko announced that Toa Eiyo has received manufacturing and marketing authorization in Japan from the Japanese Ministry of Health, Labour and Welfare for "Bisono tape 4mg" and "Bisono tape 8mg," which had been successfully developed by Nitto Denko in collaboration with Toa Eiyo as the world's first transdermal β 1-blocker patch.

Bisono tape is to be manufactured by Nitto Denko, marketed by Toa Eiyo, distributed and sold by Astellas Pharma, and promoted by both Toa Eiyo and Astellas.

Nitto Denko's technology is used for designing transdermal patch systems for various kinds of drugs to be absorbed through the skin into the body. Approximately forty million people suffer from hypertension in Japan.

Hypertension is caused by a wide variety of factors, thus patients are recommended a choice of anti-hypertensive medication either alone or in combination. Nitto Denko expects that Bisono tape, with its unique transdermal formulation, will offer a novel choice of hypertension medication for patients having difficulties with oral administration (including dysphagia) and contribute to improving patient adherence.

Bisono tape is a transdermal patch for the treatment of hypertension containing 4mg or 8mg of bisoprolol with β 1-blocking activity, which is administered once a day for 24 hours applied to the chest, upper arm or back.